BPC-157: Side Effects, Dosage and Evidence
BPC-157 is a 15-amino-acid sequence derived from a protein found in human gastric juice — which is the origin of the name, Body Protection Compound. It has more published animal research behind it than almost any other peptide sold for research use, and essentially no controlled human research. Both halves of that sentence matter.
Side effects: what is actually known
Because no controlled human trial has been completed, there is no adverse-event table to cite. What exists is animal toxicology and user reports, and they point in the same general direction.
In animal studies BPC-157 has a striking safety record: researchers repeatedly report no observable toxicity across a wide dose range, including doses far above those used for efficacy, and no LD50 was established in the studies that looked for one. That is unusual and it is the reason the compound has the reputation it does.
Reported effects in practice are mild and mostly local:
- Injection-site redness, itching or swelling — the most common complaint.
- Mild nausea or appetite change — particularly with oral use.
- Headache and lethargy — reported early in a protocol.
- Transient dizziness — occasional, shortly after administration.
How BPC-157 works
Several mechanisms appear in the literature. It upregulates VEGFR2 signalling, driving angiogenesis; it interacts with the nitric oxide system, which affects blood flow and cytoprotection; it increases growth hormone receptor expression in tendon fibroblasts, which is the proposed explanation for the tendon findings; and it modulates the inflammatory response rather than simply suppressing it.
It is also unusually stable in gastric acid for a peptide — the property that makes oral administration viable for gut-directed research, where most peptides would be destroyed before absorption.
What the research covers
Gastrointestinal healing — the strongest evidence
This is where BPC-157 originated and where the data is deepest. Rat studies show accelerated healing of gastric ulcers, protection against NSAID-induced damage, improvement in colitis models, and healing of fistulas. Given the compound came from gastric juice, this coherence between origin and effect is one of the more convincing parts of its story.
Tendon, ligament and muscle
Rat studies report accelerated healing of transected Achilles tendon, medial collateral ligament and muscle injuries, with improved biomechanical strength in healed tissue. This is the use case that drives sales — and it rests entirely on rodent data.
Nerve and bone
Animal work covers peripheral nerve regeneration after transection and improved bone healing in segmental defect models. Early-stage and preclinical.
Dosing references
| Route | Common amount | Frequency | Typical use |
|---|---|---|---|
| Subcutaneous | 250–500 mcg | 1–2× daily | Systemic, tendon, muscle |
| Oral (capsule or liquid) | 250–500 mcg | 1–2× daily | Gut-directed |
Protocols usually run four to eight weeks. There is no human dose-finding study behind these numbers; they are what circulates in practice, scaled loosely from animal work.
| Vial | Water | Concentration | 250 mcg | 500 mcg | Doses (250 mcg) |
|---|---|---|---|---|---|
| 5 mg | 2 ml | 2,500 mcg/ml | 10 units | 20 units | 20 |
| 5 mg | 2.5 ml | 2,000 mcg/ml | 12.5 units | 25 units | 20 |
| 10 mg | 2.5 ml | 4,000 mcg/ml | 6.25 units | 12.5 units | 40 |
Formula: concentration = peptide (mcg) ÷ water (ml). Volume = dose ÷ concentration. One unit on a U-100 insulin syringe = 0.01 ml. Values are for laboratory reference only.
Regulatory status
BPC-157 is not FDA approved for any human indication, and that has not changed. What has changed is its compounding status, and the timeline matters because a lot of writing on this subject is stuck at the 2023 snapshot.
- September 2023 — FDA placed BPC-157 in Category 2 of its bulk drug substances list, effectively closing the compounding-pharmacy route that had been a significant supply channel.
- February 2026 — HHS announced a policy shift on peptide compounding.
- April 2026 — FDA removed BPC-157, both acetate and free base, from Category 2.
- July 2026 — BPC-157 went before the Pharmacy Compounding Advisory Committee for 503A eligibility, alongside KPV, TB-500 and MOTS-c.
Read that carefully, because the distinction is easy to lose: removal from Category 2 is not approval, and it is not the same as being cleared for 503A compounding. It removes one specific restriction while the eligibility question stays open. BPC-157 remains available as a research chemical, and it remains prohibited by WADA at all times under S0 (non-approved substances).
BPC-157 — 5 mg / 10 mg — American Peptides
Available as vials, capsules and TB-500 blends. Given the microgram dosing, batch purity documentation matters — HPLC and mass-spec COA provided per batch.
We may earn a commission if you buy through this link (at no extra cost to you). Sold for research purposes only.
Frequently asked questions
What are the side effects of BPC-157?
No controlled human trial has catalogd them. Animal studies across a wide dose range report a notably clean toxicity profile, and user reports describe injection-site irritation, mild nausea, headache and occasional lethargy. The unresolved theoretical concern is angiogenesis: a compound that promotes blood vessel growth is not neutral in the presence of an undiagnosed tumor.
What is BPC-157 used for in research?
The largest body of work is gastrointestinal — ulcer healing, inflammatory bowel models, and protection against NSAID-induced gut damage. Beyond that, animal studies cover tendon and ligament healing, muscle injury, bone repair and nerve regeneration.
What BPC-157 dose is used in protocols?
Community protocols commonly reference 250–500 mcg once or twice daily for four to eight weeks. Animal studies used microgram-per-kilogram quantities. No human dosing trial exists, so these are practice-derived numbers rather than trial-derived.
Is oral or injectable BPC-157 better?
It depends on the target. BPC-157 is unusually stable in gastric acid, which is why oral administration is used for gut-focused research and appears in the rat studies on intestinal healing. For tendon, muscle or systemic targets, subcutaneous injection is the route used in most animal work.
Is BPC-157 legal?
It is sold in the United States as a research chemical and is not FDA approved for human use. The FDA placed it in Category 2 of its bulk drug substances list in September 2023, restricting compounding use, then removed it from Category 2 effective April 2026. Removal is not approval and not the same as 503A compounding eligibility, which remains under review. It is also prohibited by WADA. Legal status varies by country.
Sources
- Sikiric P et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 2011;17(16):1612–32. PubMed
- Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival and cell migration. Journal of Applied Physiology, 2011;110(3):774–80. PubMed
- Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine, 2017;95(3):323–333. PubMed
- Sikiric P et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Current Neuropharmacology, 2016;14(8):857–865. PubMed
- FDA. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks — BPC-157 is currently listed under “nominated but withdrawn” rather than in the active Category 2 table. FDA
- FDA Pharmacy Compounding Advisory Committee, meeting of July 23–24, 2026 — agenda covers BPC-157, KPV and TB-500 bulk drug substances. Meeting page · Briefing document (PDF)
Related guides
- TB-500: benefits, dosage and evidence
- Peptide reconstitution calculator
- Are peptides safe? Side effects by class